DGAP-News: Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: ABIVAX
/ Key word(s): Study
Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
01.12.2021 / 19:30
The issuer is solely responsible for the content of this announcement.